For healthcare professionals
Patient selection and clinical governance
Discussion of DBS belongs in a highly governed pathway for people with substantial unmet need after appropriate standard care. The materials emphasise comprehensive diagnosis, prior-treatment review, informed consent and the ability to engage in long-term follow-up.
Key point
A multidisciplinary team should assess psychiatric comorbidity, cognitive and physical health, substance-use context, relapse risk, family or social support and practical feasibility of ongoing care.
Clinical perspective
Independent outcome assessment where feasible, transparent reporting and periodic review of benefit versus harm are essential safeguards.
More context
The clinical materials supplied for this site describe outcomes within specific programs and cohorts. Such reports are valuable for hypothesis generation and service development, but they should be read alongside study methods, patient characteristics, concurrent care, missing data and outcome definitions. A sustained result in a reported cohort is not equivalent to a guaranteed outcome for an individual patient.
What to cover with a specialist team
A robust multidisciplinary review asks not only whether symptoms might improve, but also whether the person can safely participate in the full care pathway. This includes capacity and consent, psychiatric stability, substance-use risk, medical and surgical risk, ability to attend follow-up, psychosocial support and a plan for managing adverse events or changing clinical needs.
Practical preparation
- State the evidence level and uncertainty clearly when discussing options.
- Document baseline substance use, psychiatric symptoms, cognition and social functioning.
- Define monitoring intervals and escalation pathways before treatment begins.
- Review benefit, harm, adherence and patient-reported outcomes longitudinally.
Limits and safety
This article supports informed conversation; it cannot diagnose an individual or replace clinical advice. Suitability for any intervention must be determined by the responsible medical team after comprehensive assessment.
Source: Project Introduction (2026), Clinical Efficacy and Safety materials (2025) and White Paper (2026). Educational summary only; no product or commercial material is included.